Derek Nolan (Galway West, Labour)
Link to this: Individually | In context

Question 694: To ask the Minister for Health further to Parliamentary Question No. 125, the type of new technologies he is considering for the management of blood coagulation levels; the way that he believes that this will impact on people with blood coagulation problems; when he envisages these new technologies coming into use; and if he will make a statement on the matter. [29861/12]

Róisín Shortall (Dublin North West, Labour)
Link to this: Individually | In context

There is a number of new therapies for stroke prevention which have been the subject of media interest in recent months. HSE Management has been considering how these new medicines can be introduced into clinical care pathways as and when resources become available. These medicines involve complex clinical pathway changes and the HSE is working to ensure that all appropriate arrangements and controls are in place to support optimal use and achieve best value. As these new therapies will probably reduce the use of warfarin into the future, the value of patient testing with diagnostic agents such as Coagucheck will also be affected.